logo

Abbvie (ABBV)



Trade ABBV now with
  Date
  Headline
9/24/2018 10:04:06 AM S&P 500 Q2 2018 Buybacks Increase 58.7% Y-o-y To $190.6 Bln
9/21/2018 7:30:18 AM AbbVie Gets Positive CHMP Opinion For A Novel, Chemotherapy-free Combination Of VENCLYXTO With Rituximab
9/13/2018 9:21:17 AM AbbVie Presents Upadacitinib Longer-Term And Patient-Reported Outcomes Data From Phase 2b Atopic Dermatitis Study
9/13/2018 6:23:40 AM AbbVie Announces New Patient-reported Outcomes Data From Three Pivotal Phase 3 Trials On Risankizumab
9/7/2018 11:54:36 AM AbbVie (ABBV) Declares Quarterly Dividend of $ 0.96, Record Date 10/15/2018
9/7/2018 11:33:20 AM AbbVie Declares Quarterly Dividend Of $0.96, Payable Nov. 15/ Record Oct. 15
8/27/2018 7:06:09 AM AbbVie: FDA Approves IMBRUVICA Plus Rituximab For Waldenström's Macroglobulinemia
8/22/2018 8:31:55 AM AbbVie Announces Positive Topline Results From Phase 3 Extension Study Of Elagolix In Women With Uterine Fibroids
8/17/2018 4:10:51 AM New Drugs Approved In July
7/27/2018 7:40:06 AM AbbVie Q2 GAAP EPS $1.26; Adjusted EPS Up 40.8% To $2.00
7/24/2018 8:31:36 AM AbbVie Gets FDA Approval Of ORILISSA For Management Of Moderate To Severe Pain Associated With Endometriosis
7/17/2018 8:07:22 AM AbbVie Announces Patent License Agreements With Mylan Over Proposed Biosimilar Adalimumab Product
7/12/2018 1:03:08 AM AbbVie Announces Submission Of SNDA To FDA For Venetoclax